Compare TBPH & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | CCO |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2013 | 2005 |
| Metric | TBPH | CCO |
|---|---|---|
| Price | $19.26 | $2.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $27.80 | $2.10 |
| AVG Volume (30 Days) | 386.5K | ★ 8.3M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.81 |
| EPS | ★ 0.88 | 0.04 |
| Revenue | $15,386,000.00 | ★ $1,604,140,000.00 |
| Revenue This Year | $70.90 | $6.76 |
| Revenue Next Year | N/A | $4.42 |
| P/E Ratio | ★ $21.66 | $120.00 |
| Revenue Growth | N/A | ★ 6.57 |
| 52 Week Low | $7.90 | $0.81 |
| 52 Week High | $21.03 | $2.43 |
| Indicator | TBPH | CCO |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 63.48 |
| Support Level | $18.27 | $1.96 |
| Resistance Level | $19.04 | N/A |
| Average True Range (ATR) | 0.91 | 0.04 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 23.72 | 92.00 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.